TEVA (Teva Pharmaceutical Industries Limited American Depositary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by TEVA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-25 | Ronit Satchi-Fainaro | Director | Sell | — | — |
| 2026-08-25 | Amir Weiss | Chief Accounting Officer | MIXED | — | — |
| 2026-08-19 | Evan Lippman | EVP, Business Development | Sell | — | — |
| 2026-08-10 | Tal Zvi Zaks | Director | Sell | — | — |
| 2026-08-05 | Eric A Hughes | See "Remarks" | MIXED | — | — |
| 2026-08-05 | Placid Jover | See "Remarks" | MIXED | — | — |
| 2026-06-22 | Matthew Shields | EVP, Global Operations | Sell | — | — |
| 2026-06-16 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sell | — | — |
| 2026-06-08 | Ronit Satchi-Fainaro | Director | M | — | — |
| 2026-06-08 | Amir Elstein | Director | M | — | — |
| 2026-06-08 | Tal Zvi Zaks | Director | M | — | — |
| 2026-06-08 | GERALD M LIEBERMAN | Director | M | — | — |
| 2026-06-08 | Perry Nisen | Director | M | — | — |
| 2026-06-08 | Rosemary A Crane | Director | M | — | — |
| 2026-06-08 | Chen Lichtenstein | Director | M | — | — |
| 2026-06-08 | SOL J BARER | Director | M | — | — |
| 2026-06-08 | Richard D Francis | President and CEO | MIXED | — | — |
| 2026-06-08 | ROBERTO MIGNONE | Director | M | — | — |
| 2026-06-04 | Matthew Shields | EVP, Global Operations | MIXED | — | — |
| 2026-06-01 | SOL J BARER | Director | A | — | — |
| 2026-06-01 | Amir Elstein | Director | A | — | — |
| 2026-06-01 | Ronit Satchi-Fainaro | Director | A | — | — |
| 2026-06-01 | Perry Nisen | Director | A | — | — |
| 2026-06-01 | Tal Zvi Zaks | Director | A | — | — |
| 2026-06-01 | Chen Lichtenstein | Director | A | — | — |
| 2026-06-01 | GERALD M LIEBERMAN | Director | A | — | — |
| 2026-06-01 | ROBERTO MIGNONE | Director | A | — | — |
| 2026-06-01 | Rosemary A Crane | Director | A | — | — |
| 2026-05-18 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sell | — | — |
| 2026-05-18 | Evan Lippman | EVP, Business Development | MIXED | — | — |
| 2026-05-07 | Richard Daniell | EVP, Europe Commercial | Sell | — | — |
| 2026-05-07 | Amir Weiss | Chief Accounting Officer | Sell | — | — |
| 2026-05-04 | Christine Fox | EVP, U.S. Commercial | Sell | — | — |
| 2026-05-04 | Mark Sabag | See "Remarks" | Sell | — | — |
| 2026-03-19 | Mark Sabag | See "Remarks" | Sell | — | — |
| 2026-03-09 | Placid Jover | See "Remarks" | MIXED | — | — |
| 2026-03-09 | Matthew Shields | EVP, Global Operations | MIXED | — | — |
| 2026-03-09 | Christine Fox | EVP, U.S. Commercial | MIXED | — | — |
| 2026-03-09 | Eric A Hughes | See "Remarks" | MIXED | — | — |
| 2026-03-09 | Mark Sabag | See "Remarks" | M | — | — |
| 2026-03-09 | Brian Savage | Interim Chief Legal Officer | MIXED | — | — |
| 2026-03-09 | Amir Weiss | Chief Accounting Officer | M | — | — |
| 2026-03-09 | Richard Daniell | EVP, Europe Commercial | MIXED | — | — |
| 2026-03-09 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | M | — | — |
| 2026-03-09 | Richard D Francis | President and CEO | MIXED | — | — |
| 2026-03-06 | Matthew Shields | EVP, Global Operations | A | — | — |
| 2026-03-06 | Evan Lippman | EVP, Business Development | A | — | — |
| 2026-03-06 | Eric A Hughes | See "Remarks" | MIXED | — | — |
| 2026-03-06 | Richard Daniell | EVP, Europe Commercial | MIXED | — | — |
| 2026-03-06 | Placid Jover | See "Remarks" | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 2,118,455 | — |
| — | President and CEO | 1,542,471 | — |
| — | President and CEO | 1,177,529 | — |
| — | Director | 487,407 | — |
| — | Director | 448,011 | — |
| — | Director | 318,836 | — |
| — | EVP, North America Commercial | 165,381 | — |
| — | Executive VP Global Operations | 145,915 | — |
| — | See "Remarks" | 134,877 | — |
| — | Director | 130,149 | — |
| — | Director | 127,739 | — |
| — | Director | 119,807 | — |
| — | Director | 111,986 | — |
| — | Acting Chief Legal Officer | 96,983 | — |
| — | See "Remarks" | 80,760 | — |
| — | Director | 73,697 | — |
| — | Director | 73,247 | — |
| — | EVP, Chief Financial Officer | 65,621 | — |
| — | Director | 63,707 | — |
| — | EVP, U.S. Commercial | 63,647 | — |
| — | Director | 58,765 | — |
| — | EVP, Europe Commercial | 55,755 | — |
| — | Exec. VP Chief Legal Officer | 52,449 | — |
| — | See "Remarks" | 40,301 | — |
| — | EVP, North America Commercial | 33,773 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TEVA quote page; the site-wide leaderboard is on the insider transactions hub.